This study first offered evidence that long-term ω-3 supplementation may reduce incident AD risk by at least 63% but that this effect may not be at all evident from measuring blood biomarkers and may be further mediated by sex, cognitive and ApoE ε4 status [(144), Tables 2, 3]. This evidence concerns the gene APOE and Alzheimer disease.